echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Over 2 billion U.S. dollars to develop anti-TIGIT antibody GSK to add to the layout of a new generation of cancer immunotherapy

    Over 2 billion U.S. dollars to develop anti-TIGIT antibody GSK to add to the layout of a new generation of cancer immunotherapy

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, GlaxoSmithKline (GSK) and iTeos Therapeutics jointly announced that they will jointly develop and promote the anti-TIGIT antibody EOS-448, which is in phase 1 clinical development
    .


    The press release issued by GSK pointed out that this collaboration allows GSK to have three different targets (TIGIT, CD96 and PVRIG) related to the CD226 immune checkpoint pathway in research antibody therapies


    Today, GlaxoSmithKline (GSK) and iTeos Therapeutics jointly announced that they will jointly develop and promote the anti-TIGIT antibody EOS-448, which is in phase 1 clinical development


    Preliminary studies of GSK have verified the important role of CD226 signaling pathway in oncology
    .


    Therefore, the company has developed an antibody therapy targeting CD96 GSK'608 and an antibody therapy targeting PVRIG GSK'562


    ▲ GSK's R&D layout for the CD226 signal path (picture source: reference [2])

    EOS-448 developed by iTeos is an anti-TIGIT monoclonal antibody with multiple mechanisms of action
    .


    Through the cooperation with iTeos, GSK's R&D pipeline will have in-development antibody therapies targeting CD96, TIGIT, and PVRIG, providing more diversified tools for the further construction of cancer immune combination therapies


    ▲EOS-448 has multiple mechanisms of action (picture source: reference [3])

    According to the agreement, iTeos will receive an upfront payment of US$625 million and an additional US$1.
    45 billion in potential milestone payments
    .


    GSK and iTeos will share the development costs and responsibilities of EOS-448


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.